RIPK1 and metabolic dysfunction-associated steatohepatitis: Inhibition of RIPK1 kinase can reduce hepatic inflammation and liver damage in experimental NASH17,18, highlighting the importance of understanding the molecular mechanisms that control RIPK1 activation in NASH.